Replicel

[lpenergy]

While I am hoping for the best from Replicel, I have to say that I am out as an investor until I see something that provides very positive results or a similar indication. I sold half of my position upon the announcement of the delay and the other half this morning. I got in at a decent price, so a relatively small loss isn’t that bad given what could have happened.

If the results were considered to be strong (>20%), they would have raised additional funds after the results, which would have resulted in a lower shareholder stock dilution. Because they are simply using DSC cells, I do not see how they can “tweak” a formula to produce better results.

I am looking forward to any interviews, and wish the best for Replicel. If something changes, I may get back on board with buying their stock, but not at this point. It is going to be long slow slog as far as an investment.

At this point, it seems that we have to hope for any of the following:

1) The site location on the temples was sub-optimal, other spots would perform better
2) 6 months was not enough time
3) Overdosing actually hurt the results,
4) Results are compoundable
5) The treatment is more effective at stopping/slowing hair loss instead of regrowth
6) It is an augmenting treatment option
So, David Hall needs to explain why they expect future results to improve. Why did they get the high percentage hair regrowth in animals and not humans?